Stimulation of Postsynaptic α1b- and α2-Adrenergic Receptors Amplifies Dopamine-Mediated Locomotor Activity in Both Rats and Mice

Synapse

Volumn 50, Issue 4, 2003, Pages 277-284

  Villégier, Anne Sophie ^a   Drouin, Candice ^a   Bizot, Jean Charles ^b   Marien, Marc ^c   Glowinski, Jacques ^a   Colpaërt, Francis ^c   Tassin, Jean Pol ^a  

^a INSERM   (France)

^b Key Obs SA   (France)

^c INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

1b adrenergic receptor knockout mice; 6 OHDA; D amphetamine; Dexefaroxan; GBR 12783; NE depletion

Indexed keywords

1 [2 (BENZHYDRYLOXY)ETHYL] 4 (3 PHENYLALLYL)PIPERAZINE; ALPHA 1B ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; AUTORECEPTOR; DEXAMPHETAMINE; DEXEFAROXAN; DOPAMINE; DOPAMINE TRANSPORTER; NORADRENALIN; OXIDOPAMINE; POSTSYNAPTIC RECEPTOR; PSYCHOSTIMULANT AGENT; UNCLASSIFIED DRUG; YOHIMBINE; 1 (2 (DIPHENYLMETHOXY)ETHYL) 4 (3 PHENYL 2 PROPENYL)PIPERAZINE; 1-(2-(DIPHENYLMETHOXY)ETHYL)-4-(3-PHENYL-2-PROPENYL)PIPERAZINE; ADRENERGIC RECEPTOR ALPHA(1B); ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA 1 ADRENERGIC RECEPTOR; AMPHETAMINE; BENZOPYRAN DERIVATIVE; DOPAMINE RECEPTOR STIMULATING AGENT; IMIDAZOLE DERIVATIVE; PIPERAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC TRANSMISSION; DRUG POTENCY; HYPERACTIVITY; KNOCKOUT MOUSE; LOCOMOTION; MALE; MOUSE; NONHUMAN; NORADRENALIN RELEASE; NORADRENERGIC NERVE; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; RECEPTOR OCCUPANCY; STATISTICAL SIGNIFICANCE; STIMULATION; ANIMAL; ANIMAL BEHAVIOR; CEREBELLUM; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECT; HYPERKINESIA; METABOLISM; MOUSE MUTANT; PATHOPHYSIOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT; TIME;

ADRENERGIC AGENTS; AMPHETAMINE; ANIMALS; BEHAVIOR, ANIMAL; BENZOPYRANS; CEREBELLUM; DOPAMINE; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HYPERKINESIS; IMIDAZOLES; LOCOMOTION; MALE; MICE; MICE, KNOCKOUT; OXIDOPAMINE; PIPERAZINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ADRENERGIC, ALPHA-1; RECEPTORS, ADRENERGIC, ALPHA-2; TIME FACTORS;

EID: 19244370789     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/syn.10267     Document Type: Article

References (55)

1. Andersen PH. 1989. The dopamine inhibitor GBR 12909: selectivity and molecular mechanism of action. Eur J Pharmacol 166:493-504.
2. Antelman SM, Caggiula AR. 1977. Norepinephrine-dopamine interactions and behavior. Science 195:646-653.
3. Auclair A, Cotecchia S, Glowinski J, Tassin JP. 2002. D-amphetamine fails to increase extracellular dopamine levels in mice lacking alpha1b-adrenergic receptors: relationship between functional and nonfunctional dopamine release. J Neurosci 22:9150-9154.
4. Blanc G, Trovero F, Vezina P, Herve D, Godeheu AM, Glowinski J, Tassin JP. 1994. Blockade of prefronto-cortical alpha 1-adrenergic receptors prevents locomotor hyperactivity induced by subcortical D-amphetamine injection. Eur J Neurosci 6:293-298.
5. Bonnet JJ, Costentin J. 1986. GBR 12783, a potent and selective inhibitor of dopamine uptake: biochemical studies in vivo and ex vivo. Eur J Pharmacol 121:199-209.
6. Bucheler MM, Hadamek K, Hein L. 2002. Two alpha(2)-adrenergic receptor subtypes, alpha(2A) and alpha(2C), inhibit transmitter release in the brain of gene-targeted mice. Neuroscience 109:819-826.
7. Carr DB, Sesack SR. 2000. Dopamine terminals synapse on callosal projection neurons in the rat prefrontal cortex. J Comp Neurol 425:275-283.
8. Cavalli A, Lattion AL, Hummler E, Nenniger M, Pedrazzini T, Aubert JF, Michel MC, Yang M, Lembo G, Vecchione C, Mostardini M, Schmidt A, Beermann F, Cotecchia S. 1997. Decreased blood pressure response in mice deficient of the alpha1b-adrenergic receptor. Proc Natl Acad Sci USA 94:11589-11594.
9. Chergui K, Charléty P, Akaoka H, Saunier CF, Brunet JL, Buda M, Svensson TH, Chouvet G. 1993. Tonic activation of NMDA receptors causes spontaneous burst discharge of rat midbrain dopamine neurons in vivo. Eur J Neurosci 5:137-144.
10. Chopin P, Colpaert FC, Marien M. 1999. Effects of alpha-2 adrenoceptor agonists and antagonists on circling behavior in rats with unilateral 6-hydroxydopamine lesions of the nigrostriatal pathway. J Pharmacol Exp Ther 288:798-804.
11. Colpaërt FC. 1994. Noradrenergic Mechanisms in Parkinson's disease: a theory. In: Briley M, Marien MR editors. Noradrenergic mechanisms in Parkinson's disease. Boca Raton, FL: CRC Press. p 225-254.
12. Costall B, Naylor RJ. 1976. Antagonism of the hyperactivity induced by dopamine applied intracerebrally to the nucleus accumbens septi by typical neuroleptics and by clozapine, sulpiride and thioridazine. Eur J Pharmacol 35:161-168.
13. Darracq L, Blanc G, Glowinski J, Tassin JP. 1998. Importance of the noradrenaline-dopamine coupling in the locomotor activating effects of D-amphetamine. J Neurosci 18:2729-2739.
14. Darracq L, Drouin C, Blanc G, Glowinski J, Tassin JP. 2001. Stimulation of metabotropic but not ionotropic glutamatergic receptors in the nucleus accumbens is required for the D-amphetamine-induced release of functional dopamine. Neuroscience 103:395-403.
15. Davis M, Kehne JH, Commissaris RL. 1985. Antagonism of apomorphine-enhanced startle by alpha1-adrenergic antagonists. Eur J Pharmacol 108:233-241.
16. Dennis T, L'Heureux R, Carter C, Scatton B. 1987. Presynaptic alpha-2 adrenoceptors play a major role in the effects of idazoxan on cortical noradrenaline release (as measured by in vivo dialysis) in the rat. J Pharmacol Exp Ther 241:642-649.
17. Dickinson SL, Gadie B, Tulloch IF. 1988. Alpha 1- and alpha 2-adrenoreceptor antagonists differentially influence locomotor and stereotyped behaviour induced by d-amphetamine and apomorphine in the rat. Psychopharmacology (Berl) 96:521-527.
18. Drouin C, Blanc G, Villegier AS, Glowinski J, Tassin JP. 2002a. Critical role of alpha1-adrenergic receptors in acute and sensitized locomotor effects of D-amphetamine, cocaine, and GBR12783: influence of preexposure conditions and pharmacological characteristics. Synapse 43:51-61.
19. Drouin C, Darracq L, Trovero F, Blanc G, Glowinski J, Cotecchia S, Tassin JP. 2002b. Alpha1b-adrenergic receptors control locomotor and rewarding effects of psychostimulants and opiates. J Neurosci 22:2873-2884.
20. Elkhawad AO, Woodruff GN. 1975. Studies on the behavioural pharmacology of a cyclic analogue of dopamine following its injection into the brains of conscious rats. Br J Pharmacol 54:107-114.
21. Florin SM, Kuczenski R, Segal DS. 1994. Regional extracellular norepinephrine responses to amphetamine and cocaine and effects of clonidine pretreatment. Brain Res 654:53-62.
22. Gariano RF, Groves PM. 1988. Burst firing induced in midbrain dopamine neurons by stimulation of the medial prefrontal and anterior cingulate cortices. Brain Res 462:194-198.
23. Grenhoff J, Svensson TH. 1993. Prazosin modulates the firing pattern of dopamine neurons in rat ventral tegmental area. Eur J Pharmacol 233:79-84.
24. Guyenet PG, Cabot JB. 1981. Inhibition of sympathetic preganglionic neurons by catecholamines and clonidine: mediation by an alpha-adrenergic receptor. J Neurosci 1:908-917.
25. Izenwasser S, Terry P, Heller B, Witkin JM, Katz JL. 1994. Differential relationships among dopamine transporter affinities and stimulant potencies of various uptake inhibitors. Eur J Pharmacol 263:277-283.
26. Jackson DM, Anden NE, Dahlstrom A. 1975. A functional effect of dopamine in the nucleus accumbens and in some other dopamine-rich parts of the rat brain. Psychopharmacologia 45:139-149.
27. Kelly P, Seviour P, Iversen S. 1975. Amphetamine and apomorphine responses in the rat following 6-OHDA lesions of the nucleus accumbens septi and corpus striatum. Brain Res 94:507-522.
28. Kokkinidis L, Anisman H. 1978. Involvement of norepinephrine in startle arousal after acute and chronic D-amphetamine administration. Psychopharmacology 59:285-292.
29. Kokkinidis L, Anisman H. 1979. Circling behavior following systemic D-amphetamine administration: potential noradrenergic and dopaminergic involvement. Psychopharmacology 64:45-54.
30. Lategan AJ, Marien MR, Colpaert FC. 1990. Effects of locus coeruleus lesions on the release of endogenous dopamine in the rat nucleus accumbens and caudate nucleus as determined by intracerebral microdialysis. Brain Res 523:134-138.
31. Le Moal M, Stinus L, Galey D. 1976. Radiofrequency lesion of the ventral mesencephalic tegmentum: neurological and behavioral considerations. Exp Neurol 50:521-535.
32. Le Pen G, Duterte-Boucher D, Costentin J. 1998. Sensitization to the rewarding effects of the specific dopamine uptake inhibitor GBR12783. J Pharmacol Exp Ther 286:688-696.
33. Lee A, Wissekerke AE, Rosin DL, Lynch KR. 1998. Localization of alpha2C-adrenergic receptor immunoreactivity in catecholaminergic neurons in the rat central nervous system. Neuroscience 84: 1085-1096.
34. Linner L, Endersz H, Ohman D, Bengtsson F, Schalling M, Svensson TH. 2001. Reboxetine modulates the firing pattern of dopamine cells in the ventral tegmental area and selectively increases dopamine availability in the prefrontal cortex. J Pharmacol Exp Ther 297:540-546.
35. Mavridis M, Degryse AD, Lategan AJ, Marien MR, Colpaert FC. 1991. Effect of locus coeruleus lesions on parkinsonian signs, striatal dopamine and substantia nigra cell loss after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in monkeys: a possible role for the locus coeruleus in the progression of Parkinson's disease. Neuroscience 41:507-523.
36. Mohammed AK, Danysz W, Ogren SO, Archer T. 1986. Central noradrenaline depletion attenuates amphetamine-induced locomotor behavior. Neurosci Lett 64:139-144.
37. Ogren SO, Archer T, Johanson C. 1983. Evidence for a selective brain noradrenergic involvement in the locomotor stimulant effects of amphetamine in the rat. Neurosci Lett 43:327-331.
38. Pauwels PJ, Tardif S, Wurch T, Colpaërt FC. 2000. Facilitation of constitutive alpha(2A)-adrenoceptor activity by both single amino acid mutation (Thr(373)Lys) and g(alphao) protein coexpression: evidence for inverse agonism. J Pharmacol Exp Ther 292:654-663.
39. Paxinos G, Watson C. 1982. Stereotaxic atlas of the rat brain. New York: Academic Press.
40. Pijnenburg AJ, Honig WM, Van der Heyden JA, Van Rossum JM. 1976. Effects of chemical stimulation of the mesolimbic dopamine system upon locomotor activity. Eur J Pharmacol 35:45-58.
41. Rosin DL, Talley EM, Lee A, Stornetta RL, Gaylinn BD, Guyenet PG, Lynch KR. 1996. Distribution of alpha 2C-adrenergic receptor-like immunoreactivity in the rat central nervous system. J Comp Neurol 372:135-165.
42. Sallinen J, Link RE, Haapalinna A, Viitamaa T, Kulatunga M, Sjoholm B, Macdonald E, Pelto-Huikko M, Leino T, Barsh GS, Kobilka BK, Scheinin M. 1997. Genetic alteration of alpha2C-adrenoceptor expression in mice: influence on locomotor, hypothermic, and neurochemical effects of dexmedetomidine, a subtype-nonselective alpha 2-adrenoceptor agonist. Mol Pharmacol 51:36-46.
43. Sesack SR, Pickel VM. 1992. Prefrontal cortical efferents in the rat synapse on unlabeled neuronal targets of catecholamine terminals in the nucleus accumbens septi and on dopamine neurons in the ventral tegmental area. J Comp Neurol 320:145-160.
44. Shi WX, Pun CL, Zhang XX, Jones MD, Bunney BS. 2000. Dual effects of D-amphetamine on dopamine neurons mediated by dopamine and nondopamine receptors. J Neurosci 20:3504-3511.
45. Snoddy AM, Tessel RE. 1985. Prazosin: effect on psychomotor stimulant cues and locomotor activity in mice. Eur J Pharmacol 116:221-228.
46. Taghzouti K, Simon H, Herve D, Blanc G, Studler JM, Glowinski J, Le Moal M, Tassin JP. 1988. Behavioural deficits induced by an electrolytic lesion of the rat ventral mesencephalic tegmentum are corrected by a superimposed lesion of the dorsal noradrenergic system. Brain Res 440:172-176.
47. Tassin JP, Stinus L, Simon H, Blanc G, Thierry AM, Le Moal M, Cardo B, Glowinski J. 1978. Relationship between the locomotor hyperactivity induced by A10 lesions and the destruction of the fronto-cortical dopaminergic innervation in the rat. Brain Res 141: 267-281.
48. Tassin JP, Simon H, Hervé D, Blanc G, Le Moal M, Glowinski J, Bockaert J. 1982. Non-dopaminergic fibres may regulate dopamine-sensitive adenylate cyclase in the prefrontal cortex and nucleus accumbens. Nature 295:696-698.
49. Tassin JP, Studler JM, Herve D, Blanc G, Glowinski J. 1986. Contribution of noradrenergic neurons to the regulation of dopaminergic (D1) receptor denervation supersensitivity in rat prefrontal cortex. J Neurochem 46:243-248.
50. Tellez S, Colpaert FC, Marien M. 1997. Acetylcholine release in the rat prefrontal cortex in vivo: modulation by alpha2-adrenoceptor agonists and antagonists. J Neurochem 68:778-785.
51. Tessel RE, Barrett JE. 1986. Antagonism of the behavioral effects of cocaine and D-amphetamine by prazosin. Psychopharmacology 90: 436-440.
52. Vezina P, Blanc G, Glowinski J, Tassin JP. 1992. Nicotine and morphine differentially activate brain dopamine in prefrontocortical and subcortical terminal fields: effects of acute and repeated injections. J Pharmacol Exp Ther 261:484-490.
53. Whittington RA, Virag L, Morishima HO, Vulliemoz Y. 2001. Dexmedetomidine decreases extracellular dopamine concentrations in the rat nucleus accumbens. Brain Res 919:132-138.
54. Yavich L, Lappalainen R, Sirvio J, Haapalinna A, MacDonald E. 1997. Alpha2-adrenergic control of dopamine overflow and metabolism in mouse striatum. Eur J Pharmacol 339:113-119.
55. Zarow C, Lyness SA, Mortimer JA, Chui HC. 2003. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch Neurol 60:337-341.